Aarti Speciality Chemicals, a wholly-owned subsidiary of Aarti Drugs has received an approval accorded under Production Linked Incentive (PLI) scheme for pharmaceutical sector.
Government of India s Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers recently launched a Production Linked Incentive (PLI) scheme to promote domestic manufacturing by incentivising pharmaceutical manufacturers to set-up greenfield projects in India with a minimum domestic value addition in four different target segments (Two in Fermentation based - at least 90% and Two in the Chemical Synthesis based - at least 70%) with a total outlay of Rs 6,940 crore.
The objective of the scheme is achieving self-reliance and reducing import dependence in these critical Key Starting Materials (KSMs)/ Drug Intermediates/ Active Pharmaceutical Ingredients (APIs) in the country. The tenure of the scheme is from FY21 to FY30.
Shares of eight pharmaceutical companies rose by 0.5% to 3.4% after the cabinet approved Production Linked Incentive (PLI) scheme for pharmaceuticals segment.Hikal (up 3.46%), Neuland Laboratories (up 3.08%), IPCA Laboratories (up 2.85%), Alkem Laboratories (up 1.43%), Torrent Pharmaceutical (up 1.09%), Biocon (up 0.6%), Cadila Healthcare (up 0.58%) and Aurobindo Pharma (up 0.52%) were top gainers in pharmaceutical space.
The Union Cabinet on Wednesday approved Production Linked Incentive (PLI) scheme for pharmaceuticals over a period of Financial Year 2020-21 to 2028-29.
The scheme will benefit domestic manufacturers, help in creating employment and is expected to contribute to the availability of wider range of affordable medicines for consumers. The scheme is also expected to bring in investment of Rs 15,000 crore in the pharmaceutical sector.
Reported sales nilWelcure Drugs & Pharmaceuticals reported no net profit/loss in the quarter ended December 2020 as against net loss of Rs 0.01 crore during the previous quarter ended December 2019. There were no Sales reported in the quarter ended December 2020 and during the previous quarter ended December 2019.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative